Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

Cardiotoxicity induced by tyrosine kinase inhibitors

(2009) George S. Orphanos et al.   ACTA ONCOLOGICA

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

(2009) R Kumar et al.   BRITISH JOURNAL OF CANCER

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction

(2009) Lorena Zentilin et al.   FASEB JOURNAL

Nongenetic method for purifying stem cell–derived cardiomyocytes

(2009) Fumiyuki Hattori et al.   NATURE METHODS

c-kit expression identifies cardiovascular precursors in the neonatal heart

(2009) Yvonne N. Tallini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heart failure associated with sunitinib malate

(2008) Aarif Y. Khakoo et al.   CANCER

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

β-Adrenergic Receptor Mediated Protection against Doxorubicin-Induced Apoptosis in Cardiomyocytes: The Impact of High Ambient Glucose

(2008) Naohiro Yano et al.   ENDOCRINOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†

(2008) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

(2008) Shem Patyna et al.   TOXICOLOGIC PATHOLOGY

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

(2008) Yvonne Will et al.   TOXICOLOGICAL SCIENCES